Mavenir to Deliver Cloud-based 5G Solutions on AWS
27.5.2021 16:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, has announced support for deployments and integration of cloud-native telecom network functions with telco infrastructure solutions on Amazon Web Services, Inc. (AWS).
Mavenir’s collaboration with AWS allows Communications Service Providers (CSPs) to deploy Mavenir’s market leading 4G and 5G products and applications with AWS’s computing infrastructure, state of the art container deployment and management technologies, and big data analytics services. The solution is designed to scale and leverages the same tools and technologies offered by AWS to enterprise applications today. These tools are the backbone for visibility and automation for any AWS-based offering and generally referred to as Platform-as-a-Service (PaaS). This translates to offloading some of the telco application business to cloud functions, reducing complexity and putting service providers at par with organizations enjoying cost savings from cloud migrations without losing insight, performance, and control on their networks.
Another key element from this collaboration is the enablement of Private Networks and Edge deployments on AWS, powered by Mavenir’s Digital Enablement platform. With a digital app store for enterprise and various industry 4.0 applications such as IVA, AR/VR, IIoT and Robotics control, Mavenir’s Edge AI application suite is empowering an ecosystem of developers, service providers, partners, and enterprises to create and deploy applications in AWS to power digitalization and industry 4.0 with 5G.
This collaboration also lowers the network deployment time and cost for MNOs and enterprises equally fulfilling use cases of either adding 5G and edge capabilities to an existing network or a greenfield 4G/5G network launch leveraging public clouds.
“The collaboration with Mavenir and AWS allows us to build out our 5G network and messaging platforms in a true cloud-native manner, harnessing the speed and agility that the AWS cloud brings along with Mavenir’s expertise in deploying and operating cloud-native network functions," said Sidd Chenumolu, Vice President of Technology Development, DISH. “Together, we will enable our customers to take full advantage of the potential of 5G, reimagining wireless connectivity and giving our customers the ability to customize their network experience.”
“Working with AWS enables us to bring new customer-focused 5G use cases and 5G deployments to the market faster and with unique capabilities to realize true 5G potential,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “Mavenir’s solutions are designed to support full public cloud as well as hybrid cloud deployments.”
"We’re delighted to collaborate with Mavenir to offer voice and messaging solutions for core network and RAN customers along with AI/ML solutions for orchestration and observability,” said Amir Rao, General Manager Telco Solution Portfolio and Tech Alliances, AWS. “Together, we are providing true cloud native benefits to CSP customers, combining Mavenir’s expertise in the NFV market with the global scale of the AWS infrastructure to meet industry challenges of agility, scaling, slicing, and resiliency.”
Mavenir’s 4G and 5G deployments on AWS provides unique capabilities, including:
- Integration of Mavenir’s cloud-native Open RAN (vDU, vCU-CP, vCU-UP), Converged 4G/5G Packet Core, IMS, and Messaging with Amazon Elastic Kubernetes Service (Amazon EKS) anywhere supporting AWS Outposts.
- Use of AWS platform services and tools to deploy and manage cloud native network functions.
- Options for existing deployments to migrate Mavenir’s IMS core, voice, and messaging solutions to Amazon EKS and Amazon Elastic Compute Cloud (Amazon EC2) infrastructure.
- Mavenir’s Orchestration and Network Slicing solutions to manage hybrid cloud workloads running on AWS.
- Adoption of AWS for centrally managed telco workloads on far-edge, network edge and core simultaneously.
- Deployment of Mavenir’s standards compliant observability framework, RIC, NWDAF, AIOps and Analytics platform in AWS to collect the data from various AWS nodes in a centrally managed data lake and process the data using AI/ML for network wide insights and optimization.
- Integration of Mavenir’s telecom adaptation layer (Telco PaaS) as a common open source-based platform adaptation layer designed for telco specific workloads to support various carrier grade requirements on top of Amazon EKS and AWS PaaS functions.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005102/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Loren Guertin
MatterNow
mavenir@matternow.com
Kevin Taylor
GlobalResultsPR
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
